Used as a potent carbonic anhydrase inhibitor, this compound shows significant application in the development of therapeutic agents for glaucoma. It helps reduce intraocular pressure by inhibiting the production of aqueous humor and fluid buildup in the eye. Its selective action against specific carbonic anhydrase isoforms, such as CA II, enhances efficacy while minimizing systemic side effects. Additionally, it has been explored for anticonvulsant activity and potential use in treating epilepsy. The compound’s structure allows for improved metabolic stability and bioavailability, making it a valuable scaffold in designing new neuroactive and anti-infective drugs. Furthermore, research indicates potential anticancer activity, as isoforms CA IX and XII are overexpressed in certain cancer cells, where it may inhibit tumor growth; however, studies are preclinical and require further validation for efficacy and safety.